Abstract Number: 831 • 2016 ACR/ARHP Annual Meeting
Immunosuppression May Prevent Interstitial Lung Disease in Systemic Sclerosis
Background/Purpose: Interstitial lung disease (ILD) is a leading cause of premature mortality in systemic sclerosis (SSc). Immunosuppression is used for treatment of established disease. However,…Abstract Number: 839 • 2016 ACR/ARHP Annual Meeting
Immunosuppression Does Not Prevent Severe Gastrointestinal Disease in Systemic Sclerosis
Background/Purpose: Severe gastrointestinal (GI) disease is associated with considerable morbidity and high mortality in systemic sclerosis (SSc). There are no known preventative treatments. We wished…Abstract Number: 283 • 2015 ACR/ARHP Annual Meeting
Altered Serum Fatty Acid Profiles in Patients with Polymyositis or Dermatomyositis Compared to Healthy Individuals and in Relation to Immunosuppressive Treatment
Background/Purpose: Polymyositis (PM) and dermatomyositis (DM) are chronic autoimmune diseases, characterized by muscle fatigue. Despite conventional immunosuppressive treatment including high doses of glucocorticoids, only a…Abstract Number: 831 • 2015 ACR/ARHP Annual Meeting
Mycophenolate Decreases the Frequency of Endoscopic Therapy for Gastric Antral Vascular Ectasia in Patients with Systemic Sclerosis
Background/Purpose: Gastric antral vascular ectasia (GAVE) is an increasingly recognized cause of upper gastrointestinal bleeding in patients with systemic sclerosis (SSc). These patients may require…Abstract Number: 923 • 2015 ACR/ARHP Annual Meeting
Perceptions of Infectious Risk of Immunosuppressive Medications Among Treating Physicians
Background/Purpose: Physicians often encounter patients who are treated with immunosuppressive agents and must consider the risk of infection that the medications may pose. We explored…Abstract Number: 1397 • 2015 ACR/ARHP Annual Meeting
Successful Treatment of Cardiac Sarcoidosis with Biologic and Immunosuppressive Combination Therapy
Background/Purpose: Although cardiac involvement is symptomatic in only 5% of patients with sarcoidosis, it is considered an important prognostic factor and the second leading cause…Abstract Number: 1567 • 2015 ACR/ARHP Annual Meeting
Occurrence of Serious Infection in Patients with Rheumatoid Arthritis Treated with Biologics and Denosumab Observed in a Clinical Setting
Background/Purpose: Previous studies combining immunosuppressive biologics have shown an increased risk of infections. Few studies have examined the risk of infection with concurrent use of…Abstract Number: 1988 • 2015 ACR/ARHP Annual Meeting
Efficacy and Safety of Mizoribine for Polymyalgia Rheumatica: Analysis of 47 Cases
Background/Purpose: Polymyalgia rheumatic (PMR) is an inflammatory rheumatic disease characterized by aching and morning stiffness of body, which is seen almost exclusively in adults over…Abstract Number: 2502 • 2015 ACR/ARHP Annual Meeting
Implementation of New Pneumococcal Vaccination Recommendations in an Academic Rheumatology Clinic
Background/Purpose: Invasive pneumococcal disease is approximately four times more common among patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) compared to healthy counterparts.…Abstract Number: 3193 • 2015 ACR/ARHP Annual Meeting
Immunomodulatory and Antiviral Therapies in a Mouse Model of Chikungunya Viral Arthritis
Background/Purpose: Chikungunya virus (CHIKV) is a rapidly emerging arthritogenic mosquito-borne alphavirus that has infected more than 1 million individuals in the Western Hemisphere since 2014. …Abstract Number: 3262 • 2015 ACR/ARHP Annual Meeting
The Influence of Immunosuppressive Therapy on Microangiopathy in Systemic Sclerosis As Measured with Nailfoldcapillaroscopy
Background/Purpose: Microangiopathy in systemic sclerosis (SSc), as visualized by nailfold videocapillaroscopy (NVC) is a dynamic and sequential process1. In time, NVC patterns progress from early,…Abstract Number: 1677 • 2014 ACR/ARHP Annual Meeting
Association of Gastrointestinal Symptoms with Immunosuppressant Use in the Prospective Registry of Early Systemic Sclerosis Cohort
Background/Purpose: The Prospective Registry of Early Systemic Sclerosis (PRESS) is a multicenter incident cohort study of patients with early diffuse cutaneous systemic sclerosis (dcSSc; <…Abstract Number: 1661 • 2014 ACR/ARHP Annual Meeting
Are Repeat Renal Biopsies Important in Managing Lupus Nephritis Flares?
Background/Purpose Lupus nephritis (LN) is the major cause of morbidity and mortality in patients with systemic lupus erythematosus. The role of repeat kidney biopsies (RB)…Abstract Number: 1260 • 2014 ACR/ARHP Annual Meeting
The Early Use of Cyclosporine Is Beneficial for Long-Term Prognosis in Patients of Polymyositis/Dermatomyositis-Associated Interstitial Lung Disease with Anti- Synthetase Antibodies
Background/Purpose: Interstitial lung disesases (ILD) is the most common cause of mortality in polymyosotis (PM) and dermatomyositis (DM). Cyclosporine had been reported to improve clinical…Abstract Number: 1051 • 2014 ACR/ARHP Annual Meeting
Rates of Renal Remission with Immunosuppressives in Lupus Nephritis: A Systematic Review and Network Meta-Analysis
Background/Purpose To compare renal remission rates with immunosuppressives by performing a systematic review and network meta-analyses (NMA) of RCTs of lupus nephritis. Methods We performed…